---
title: "Precigen: Successful Proof Of Platform, But Cash Worries Remain"
date: "2025-02-10 09:40:03"
summary: "Richard Drury  Precigen (NASDAQ:PGEN) develops cell and gene therapies using its AdenoVerse and UltraCAR-T platforms. I could devote an entire article on these platforms, and since I haven’t covered PGEN before, it would not be out of place. However, since they have data, a"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688767071/image_1688767071.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![A graph moving up](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688767071/image_1688767071.jpg?io=getty-c-w750) 



Richard Drury





Precigen (NASDAQ:[PGEN](https://seekingalpha.com/symbol/PGEN "Precigen, Inc.")) develops cell and gene therapies using its AdenoVerse and UltraCAR-T platforms. I could devote an entire article on these platforms, and since I haven’t covered PGEN before, it would not be out of place. However, since they have data, a

[seekalpha_articles](https://seekingalpha.com/article/4756527-precigen-successful-proof-of-platform-but-cash-worries-remain)
